Scope and patent-claim landscape of US Patent 11,077,106: erdafitinib dosing and phosphate monitoring for FGFR-altered urothelial cancer
US Patent 11,077,106 claims a specific, regimen-level method for treating urothelial cancer with FGFR genomic alterations using erdafitinib with (1) a defined starting daily dose, (2) a defined phosphate-monitoring time point in cycle 1, and (3) phosphate-threshold driven dose escalation or interruption rules. The claims are narrow to serum phosphate thresholds and schedule timing, but they are broad in that they cover multiple FGFR genomic alteration types (including multiple fusion partners and mutation codons) and multiple clinical urothelial settings (metastatic or surgically unresectable).
What does US Patent 11,077,106 claim for erdafitinib in FGFR-altered urothelial cancer?
Core independent claim (Claim 1)
Claim 1 is a method claim with three functional blocks:
-
Patient population
- “A method for the treatment of urothelial cancer harboring at least one FGFR genomic alteration.”
-
Drug administration schedule and starting dose
- “administering… 8 mg of erdafitinib daily on a continuous basis.”
-
Serum phosphate measurement and response-based titration logic during first cycle
- “measuring the serum phosphate levels… on a treatment day during the first cycle…”
- Then one of three branches based on serum phosphate level:
- < 5.5 mg/dL: continue/adjust to 9 mg daily, continuous
- 5.5 mg/dL to <7 mg/dL: continue 8 mg daily, continuous
- ≥ 7 mg/dL: interrupt erdafitinib temporarily
Dependent claims refine the timing, increments, and endpoints
Claims 2-23 add dosing form factors, timing windows, and additional interruption and discontinuation triggers at higher phosphate levels.
Phosphate thresholds and dosing rules embedded in Claim 1
| Serum phosphate level (mg/dL) |
Claim 1 action |
| < 5.5 |
Increase to 9 mg daily (continuous) |
| ≥ 5.5 and < 7 |
Keep 8 mg daily (continuous) |
| ≥ 7 |
Temporarily interrupt |
Additional escalation/interruption/discontinuation logic in dependent claims
The landscape in Claims 6-11 adds further levels that are not spelled out in Claim 1’s three-branch structure:
| Serum phosphate level (mg/dL) |
Dependent claim language |
| ≥ 7 to ≤ 9 |
Interrupt until < 5.5, then restart at 8 mg daily (Claim 7) |
| > 9 |
Interrupt until < 5.5 and restart at a lower dose (Claims 8, 11) |
| Lower dose example |
6 mg daily continuous (Claim 9) |
| > 10 |
Permanently discontinue (Claim 10) |
| > 10 alternative pathway |
Interrupt until <5.5 and restart at lower dose (Claim 11) |
Timing constraint: “day 14 ±2” in first cycle
Claims 3 and 4 specify when phosphate is measured:
- Day 14 ± 2 days (Claim 3)
- Day 14 (Claim 4)
This timing element matters because it narrows method coverage from any phosphate testing to a cycle-1 schedule anchored around Day 14.
How broad are the FDA-relevant “FGFR genomic alteration” categories within US 11,077,106?
Claim 1 is broad on the definition of the eligible tumor biomarker: “at least one FGFR genomic alteration.” Dependent claims narrow and enumerate specific alterations.
Specific FGFR alterations called out in dependent claims
FGFR3-TACC3 translocation
- Claim 12: “FGFR3-TACC3 translocation”
FGFR3 mutation codons explicitly listed
- Claim 13: FGFR3 R248C, S249C, G370C, Y373C
FGFR fusions enumerated
- Claim 14: includes:
- FGFR3:TACC3 v1; FGFR3:TACC3 v3; FGFR3:TACC3 Intron
- FGFR3:BAIAP2L1
- FGFR2:AFF3; FGFR2:BICC1; FGFR2:CASP7; FGFR2:CCDC6; FGFR2:OFD1
A subset focus
- Claim 15 ties Claim 14 to “FGFR3-TACC3 fusion.”
Clinical urothelial setting
- Claim 16: “urothelial cancer is metastatic or surgically unresectable”
Then Claim 17-19 parallel Claims 12-14 while tying the same biomarkers to the metastatic/unresectable setting.
Net effect on scope:
The claim set is “biomarker-broad” (covers multiple FGFR aberration types) while “procedure/nursing-broad” (dosing interruption and restart are included). The narrowest axis is the phosphate threshold framework and timing.
What dosing and formulation variants are covered?
US 11,077,106 includes claim coverage that can capture practical formulation execution for dose changes.
Once-daily administration
- Claim 2: 8 mg once daily
- Claim 5: 9 mg once daily
Dosage-unit composition examples
- Claim 20: 8 mg administered as two formulations
- Claim 21: two tablets each 4 mg
- Claim 22: 9 mg administered as three formulations
- Claim 23: three tablets each 3 mg
Implication for design-around:
A competitor using different tablet strengths or capsule-based dosing could still practice the method if it administers the same total daily erdafitinib amount and follows phosphate-driven logic. The claim language focuses on the “two formulations” / “three formulations” in the dependent claims, but Claim 1 itself does not require multi-tablet splits.
Is the claim set limited to “first cycle day 14” monitoring?
The method is explicitly tied to:
- phosphate measurement “during the first cycle” (Claim 1)
- measurement day “day 14 ± 2” (Claim 3)
- measurement day “day 14” (Claim 4)
Claims 6-11 specify higher phosphate triggers but do not add alternative timing constructs beyond “when” thresholds are met, implying the titration is tied to the treatment day(s) on which those decisions are made. Still, the only explicit schedule anchor in the claim text is the Day 14 ±2 measurement in cycle 1.
Scope conclusion:
If a competitor runs phosphate monitoring outside the “first cycle” or without a Day 14 ±2 measurement decision point, it avoids key elements required by Claims 1/3/4. If monitoring is performed but decision rules deviate from threshold/dose logic, it may also escape.
How strong is the US patent estate for this exact erdafitinib dosing algorithm?
A complete “strength” assessment normally depends on:
- the application and patent file history,
- claim construction history,
- examiner arguments,
- prosecution outcome and any amendments,
- related patents in the same family (priority chain),
- and any post-grant validity rulings.
Those inputs require direct access to the patent’s record and claim set beyond the excerpt provided. With only claim text, a full comparative strength evaluation across the US estate cannot be completed.
Scope-only strength proxy available from the claims:
- The independent claim is tightly defined around:
- 8 mg starting dose,
- continuous daily dosing,
- serum phosphate thresholds (<5.5, 5.5 to <7, ≥7),
- and cycle 1 monitoring with an anchored “day 14” window (via dependent claims).
- The dependent claims expand practical titration options at higher phosphate levels (>9 and >10), increasing enforcement surface against real-world management.
Practical conclusion:
The claim set is enforcement-friendly against providers who follow Day 14 phosphate checks and threshold-driven interruptions/escalations as written. It is less likely to read on broad “erdafitinib + FGFR alteration” regimens that use different monitoring timing or different phosphate cutoffs.
Where are the main legal design-around opportunities embedded in Claim 1?
From an infringement-avoidance lens, the claim’s required elements create discrete substitution points:
-
Starting dose
- Claim 1 requires 8 mg daily as the initial continuous dose.
-
Phosphate measurement timing anchor
- Claim 1 requires measurement during first cycle; Claims 3/4 anchor Day 14 ±2 or Day 14.
-
Threshold logic
- Branches must match:
- <5.5 → 9 mg daily
- 5.5 to <7 → 8 mg daily
- ≥7 → temporary interruption
-
Treatment interruption mechanics
- Dependent claims specify restart triggers and lower-dose examples.
-
Continuous basis
- The method emphasizes continuous dosing “on a continuous basis.” Interruption beyond the claimed triggers could be an argument depending on fact pattern.
Design-around is therefore less about substituting drug (erdafitinib remains central) and more about altering the algorithm.
When does US 11,077,106 expire and how does that affect generic entry risk?
A legal exclusivity and expiration timeline requires:
- priority date(s),
- patent term adjustment (PTA),
- terminal disclaimer status,
- and any regulatory exclusivity stacking (Orange Book listing, pediatric exclusivity).
Those details are not provided in the prompt. Without them, a correct exclusivity calendar cannot be produced.
Scope conclusion:
The claim set targets a specific erdafitinib monitoring and titration regimen, so generic entry risk in the US depends on whether generic erdafitinib labels (and clinical protocols) would induce physicians to follow the patented algorithm. For Paragraph IV-type challenges, the controlling question is still method practice, not erdafitinib identity alone.
What does the claim coverage imply for Paragraph IV challenges or biosimilar risk?
Generic risk
For small-molecule erdafitinib, biosimilar logic does not apply. Generic risk is typically about whether a generic product label or proposed use would be “carved out” of patented method steps.
However, method claims like this can be asserted against parties practicing the patented steps, including prescribing and treating physicians (depending on enforcement strategy and jurisdictional doctrine).
Paragraph IV challenge posture
An ANDA Paragraph IV “skinny label” strategy would need to address whether the label and practice would still lead to the claimed dosing/titration algorithm:
- starting at 8 mg daily,
- measuring serum phosphate on day 14 ±2 during cycle 1,
- and adjusting/escalating/interrupting exactly by the stated thresholds.
A successful carve-out would likely require a label section change or directions that materially diverge from the claimed protocol.
How many claim elements must a generics-and-clinic design around simultaneously?
At minimum (Claim 1):
- FGFR-altered urothelial cancer
- erdafitinib
- 8 mg daily continuous starting dose
- serum phosphate measurement during first cycle
- threshold-based decisions:
- <5.5 to 9 mg daily
- 5.5 to <7 to 8 mg daily
- ≥7 to interrupt temporarily
With dependent claims, additional elements:
- Day 14 ±2 or day 14 measurement schedule
- once-daily dosing
- additional higher-threshold actions (>9, >10)
- specific tablet splitting (4 mg tablets for 8 mg; 3 mg tablets for 9 mg) via specific dependent claims.
This multi-element structure means partial deviation can still infringe if enough elements are met. The most robust design-around is to disrupt at least one mandatory element of Claim 1’s algorithmic chain (dose start, timing, or threshold logic).
Key Takeaways
- US 11,077,106 claims a method for treating FGFR genomic alteration-positive urothelial cancer with erdafitinib using a phosphate-monitoring and threshold-driven dose adjustment algorithm.
- The independent claim requires starting at 8 mg daily, continuous dosing, cycle 1 serum phosphate monitoring, and specific actions at <5.5 mg/dL, 5.5 to <7 mg/dL, and ≥7 mg/dL.
- Dependent claims strengthen enforcement by adding a Day 14 ±2 monitoring window, higher phosphate triggers (>9 and >10), and practical tablet-splitting examples (4 mg and 3 mg tablets).
- The strongest enforcement path is against clinical practices that follow the Day 14 phosphate check and apply the exact cutoffs and restart rules.
FAQs
1) Does US 11,077,106 protect erdafitinib itself or only the treatment method?
It protects a method of treatment, not the drug molecule or formulation as such.
2) If a patient is started on a dose other than 8 mg, is Claim 1 still implicated?
Claim 1 requires 8 mg daily on a continuous basis, so starting at another dose generally avoids that element.
3) Are all FGFR alterations treated the same under the patent?
Claim 1 covers “at least one FGFR genomic alteration,” and dependent claims enumerate specific FGFR3 mutations and several FGFR fusions, including FGFR3-TACC3.
4) Does measuring phosphate at a different day than Day 14 ±2 avoid infringement?
Dependent Claims 3/4 turn on the Day 14 ±2 or Day 14 timing; Claim 1 still requires “during the first cycle,” but the Day 14-based narrowing is a major additional constraint.
5) Can a label carve-out prevent enforcement of this method patent?
A carve-out can reduce inducement risk if it prevents practice of the claimed algorithm, but infringement turns on whether the patented steps are actually performed.
References
- US Patent 11,077,106 (claims provided in prompt).
